🇺🇸 FDA
Pipeline program

ISIS-FXIRx Dose #2

ISIS 416858-CS3

Phase 2 small_molecule completed

Quick answer

ISIS-FXIRx Dose #2 for Venous Thromboembolism is a Phase 2 program (small_molecule) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
IONIS PHARMACEUTICALS INC
Indication
Venous Thromboembolism
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials